227 related articles for article (PubMed ID: 22455637)
1. [Application of succinylacetone levels measurement in the blood and urine in the diagnosis of tyrosinemia type 1].
Han LS; Ye J; Qiu WJ; Zhang HW; Wang Y; Ji WJ; Gao XL; Li XY; Jin J; Gu XF
Zhonghua Er Ke Za Zhi; 2012 Feb; 50(2):126-30. PubMed ID: 22455637
[TBL] [Abstract][Full Text] [Related]
2. Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type 1 using UPLC-MS/MS.
Al-Dirbashi OY; Rashed MS; Jacob M; Al-Ahaideb LY; Al-Amoudi M; Rahbeeni Z; Al-Sayed MM; Al-Hassnan Z; Al-Owain M; Al-Zeidan H
Biomed Chromatogr; 2008 Nov; 22(11):1181-5. PubMed ID: 18651606
[TBL] [Abstract][Full Text] [Related]
3. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs.
la Marca G; Malvagia S; Pasquini E; Innocenti M; Fernandez MR; Donati MA; Zammarchi E
Rapid Commun Mass Spectrom; 2008; 22(6):812-8. PubMed ID: 18278819
[TBL] [Abstract][Full Text] [Related]
4. Analysis of succinylacetone, as a Girard T derivative, in urine and dried bloodspots by flow injection electrospray ionization tandem mass spectrometry.
Johnson DW; Gerace R; Ranieri E; Trinh MU; Fingerhut R
Rapid Commun Mass Spectrom; 2007; 21(1):59-63. PubMed ID: 17133337
[TBL] [Abstract][Full Text] [Related]
5. Newborn screening for hepatorenal tyrosinemia: Tandem mass spectrometric quantification of succinylacetone.
Sander J; Janzen N; Peter M; Sander S; Steuerwald U; Holtkamp U; Schwahn B; Mayatepek E; Trefz FK; Das AM
Clin Chem; 2006 Mar; 52(3):482-7. PubMed ID: 16439608
[TBL] [Abstract][Full Text] [Related]
6. Determination of succinylacetone in dried blood spots and liquid urine as a dansylhydrazone by liquid chromatography tandem mass spectrometry.
Al-Dirbashi OY; Rashed MS; Brink HJ; Jakobs C; Filimban N; Al-Ahaidib LY; Jacob M; Al-Sayed MM; Al-Hassnan Z; Faqeih E
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 831(1-2):274-80. PubMed ID: 16384749
[TBL] [Abstract][Full Text] [Related]
7. Tandem mass spectrometric assay of succinylacetone in urine for the diagnosis of hepatorenal tyrosinemia.
Rashed MS; Al-Ahaidib LY; Al-Dirbashi OY; Al Amoudi M; Al-Sayed MM; Rahbeeni Z; Al-Hassnan Z; Al-Dbaas A; Al-Owain M; Ni Luanaigh M
Anal Biochem; 2005 Apr; 339(2):310-7. PubMed ID: 15797572
[TBL] [Abstract][Full Text] [Related]
8. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I.
Magera MJ; Gunawardena ND; Hahn SH; Tortorelli S; Mitchell GA; Goodman SI; Rinaldo P; Matern D
Mol Genet Metab; 2006 May; 88(1):16-21. PubMed ID: 16448836
[TBL] [Abstract][Full Text] [Related]
9. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots.
Allard P; Grenier A; Korson MS; Zytkovicz TH
Clin Biochem; 2004 Nov; 37(11):1010-5. PubMed ID: 15498530
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a novel, commercially available mass spectrometry kit for newborn screening including succinylacetone without hydrazine.
Metz TF; Mechtler TP; Merk M; Gottschalk A; Lukačin R; Herkner KR; Kasper DC
Clin Chim Acta; 2012 Aug; 413(15-16):1259-64. PubMed ID: 22521492
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of factors influencing accuracy in the analysis of succinylacetone in dried blood spots.
Peng M; Liu L; Peng L
Clin Chim Acta; 2012 Aug; 413(15-16):1265-9. PubMed ID: 22522056
[TBL] [Abstract][Full Text] [Related]
12. Determination of urinary succinylacetone by capillary electrophoresis for the diagnosis of tyrosinemia type I.
Cansever MS; Erim FB
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Apr; 818(2):309-11. PubMed ID: 15734174
[TBL] [Abstract][Full Text] [Related]
13. Newborn screening for Tyrosinemia type 1 using succinylacetone - a systematic review of test accuracy.
Stinton C; Geppert J; Freeman K; Clarke A; Johnson S; Fraser H; Sutcliffe P; Taylor-Phillips S
Orphanet J Rare Dis; 2017 Mar; 12(1):48. PubMed ID: 28274233
[TBL] [Abstract][Full Text] [Related]
14. The successful inclusion of succinylacetone as a marker of tyrosinemia type I in Tuscany newborn screening program.
la Marca G; Malvagia S; Funghini S; Pasquini E; Moneti G; Guerrini R; Zammarchi E
Rapid Commun Mass Spectrom; 2009 Dec; 23(23):3891-3. PubMed ID: 19902423
[No Abstract] [Full Text] [Related]
15. [Mutation analysis of FAH gene in patients with tyrosinemia type 1].
Dou LM; Fang LJ; Wang XH; Lu W; Chen R; Li LT; Zhao J; Wang JS
Zhonghua Er Ke Za Zhi; 2013 Apr; 51(4):302-7. PubMed ID: 23927806
[TBL] [Abstract][Full Text] [Related]
16. Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots.
Turgeon C; Magera MJ; Allard P; Tortorelli S; Gavrilov D; Oglesbee D; Raymond K; Rinaldo P; Matern D
Clin Chem; 2008 Apr; 54(4):657-64. PubMed ID: 18281422
[TBL] [Abstract][Full Text] [Related]
17. [Clinical and genetic analysis of a patient with tyrosinemia type I but without elevated succinylacetone].
Guo L; Jiao B; Liu F
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 May; 36(5):472-476. PubMed ID: 31030436
[TBL] [Abstract][Full Text] [Related]
18. Urinary Succinylacetone Analysis by Gas Chromatography-Mass Spectrometry (GC-MS).
Chen H; Yu C
Methods Mol Biol; 2016; 1378():281-90. PubMed ID: 26602140
[TBL] [Abstract][Full Text] [Related]
19. Quantification of succinylacetone in urine of hepatorenal tyrosinemia patients by HPLC with fluorescence detection.
Al-Dirbashi OY; Jacob M; Al-Ahaidib LY; Al-Qahtani K; Rahbeeni Z; Al-Owain M; Rashed MS
Clin Chim Acta; 2006 Mar; 365(1-2):243-8. PubMed ID: 16243307
[TBL] [Abstract][Full Text] [Related]
20. A GC/MS validated method for the nanomolar range determination of succinylacetone in amniotic fluid and plasma: an analytical tool for tyrosinemia type I.
Cyr D; Giguère R; Villain G; Lemieux B; Drouin R
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 832(1):24-9. PubMed ID: 16414314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
